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Live attenuated influenza vaccine
IgA
IgG subclass
Antibody responsea b s t r a c t
Two different influenza vaccines are generally used in many countries; trivalent live attenuated influenza
vaccine (LAIV3) and trivalent inactivated influenza vaccine (IIV3). Studies comparing the antibody
response to IIV3 and LAIV3 commonly investigate the seroprotective response by hemagglutination-
inhibition (HI) assay. However, there is limited data regarding comparative analysis of IgG subclass
and IgA responses induced by LAIV3 and IIV3.
Fifteen children <5 years received 2 doses of LAIV3 while 14 children aged 10–17 years received one
dose. In addition, 15 adults were vaccinated with either intranasal LAIV3 or intramuscular IIV3. We ana-
lyzed the H3N2 humoral responses by HI assay and the hemagglutinin (HA) specific IgG1, IgG2, IgG3,
IgG4 and IgA1 responses by ELISA. Furthermore, we investigated the avidity of induced IgG antibodies.
Pre-existing seroprotective HI antibodies were present in adults (73%) previously vaccinated with IIV3.
Vaccination resulted in a significant increase in HI titers in all groups, except LAIV3 vaccinated adults.
Furthermore, a negative correlation between age and HI titers in LAIV3 vaccinated subjects was observed
post-vaccination. LAIV3 in children and IIV3 in adults induced HA-specific IgG1, low IgG3 but no IgG2 or
IgG4. Moreover, significant IgA1 responses were only induced in children. Interestingly, IIV3 and LAIV3
induced IgG antibodies with comparable and significantly augmented avidity post-vaccination in chil-
dren and adults.
Our results suggest that age and/or exposure history play a significant role in determining the antibody
response.
Clinical trial registry: ClinicalTrials.gov NCT01003288 and NCT01866540
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza is one of the most common respiratory infections rep-
resenting a cause of concern in the field of public health [1]. Each
year, seasonal influenza infection can cause up to 5 million severe
cases and between 250,000 and 500,000 deaths worldwide [2,3].
Vaccination remains the most effective preventative measureagainst infection and limits morbidity and mortality caused by
influenza. The effectiveness of influenza vaccination varies in dif-
ferent age groups and by vaccine formulations [4–6].
Currently, there are two main types of seasonal influenza vacci-
nes: the trivalent inactivated influenza vaccine (IIV3) and trivalent
live attenuated influenza vaccine (LAIV3). Although recently
quadrivalent vaccines containing two B strain lineages have
become available, namely LAIV4 and IIV4. Studies that have inves-
tigated the antibody responses after IIV3 and LAIV3 vaccination
have focused on the classic serological assays, such as
hemagglutination-inhibition assay (HI) and microneutralization
assay (MN) [7–10]. These antibody responses are mainly directed
Fig. 1. Study design. Fifteen healthy children <5 years old, 14 children aged 10–17
and 15 adults were vaccinated with Live Attenuated Influenza Vaccine (LAIV3). In
addition, 15 adults were vaccinated with Trivalent Inactivated Influenza Vaccine
(IIV3) as a control. Children <5 received 2 vaccine doses, 28 days apart, while the
remaining participants received 1 dose. Plasma was collected at day of vaccination
(D0) in all subjects. Additional plasma was collected at D28 and D56 post-
vaccination in children <5, day 28 (D28) in children 10–17 years old, D28 in LAIV3
vaccinated adults and at day 21 (D21) in IIV3 vaccinated adults.
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important functions essential for infection, such as recognition of
host cells’ receptors and fusion of viral and endosomal membranes.
Antibodies to HA are measured by classical serology as surrogate
correlates of protection. However, there are no established corre-
lates of protection for LAIV. Furthermore, there is limited data doc-
umenting the differences in systemic IgG and IgA subclass
responses after vaccination in children and adults.
IgG levels are important for influenza vaccination responses and
protection [11,12]. The four subclasses of IgG in humans; IgG1,
IgG2, IgG3 and IgG4, differ in function [13]. In particular, IgG1
and IgG3 are involved in many important immunological func-
tions, including complement fixation, opsonization as well as virus
neutralization [6]. Two IgA subclasses, IgA1 and IgA2 are involved
in the protection in the local mucosa, including the upper respira-
tory tract where the influenza virus causes infection [14,15].
We conducted this study to investigate the differences in HA-
specific IgG subclass and IgA antibody responses induced by LAIV3
in children and adults and by IIV3 in adults. We also evaluated the
quality of the induced IgG antibodies.2. Materials and methods
2.1. Study design
All participants >12 years and parents provided written
informed consent before inclusion in the study, which had ethical
and regulatory approval (ClinicalTrials.gov NCT01003288 and
NCT01866540). All individuals were vaccinated during the winters
of 2012 and 2013. Fifteen healthy children <5 years of age received
two doses of LAIV3, 28 days apart, while 14 healthy children aged
10–17 years old received 1 dose of LAIV as recommended by the
manufacturer. Fifteen healthy adults received a single dose of
LAIV3. As a comparator control, an additional 15 adults were vac-
cinated with IIV3. All IIV3-vaccinated adults were healthcare work-
ers and had received prior seasonal influenza vaccination, as well
as pandemic H1N1 vaccine in 2009 (Table 1).
The LAIV3 (FluenzTM, AstraZeneca, UK) for 2012–2013 contained
107.0±0.5 FFU for each of A/California/7/2009(H1N1)pdm09, A/Vic-
toria/361/2011(H3N2), and B/Wisconsin/1/2010. The 2013–2014
LAIV3 vaccine contained A/California/7/2009 (H1N1)pdm09, A/Vic-
toria/361/2011 - H3N2-like strain (A/Texas/50/2012) and B/Mas-
sachusetts/02/2012. The IIV3 (split-vaccine) (Vaxigrip, Sanofi
Pasteur, France) containing 15 lg HA of A/California/07/2009-like
virus (H1N1)pdm09, A/Texas/50/2012 (H3N2) and B/Mas-
sachusetts/02/2012. Serum samples were collected prior to vacci-
nation, and after vaccination (Fig. 1). All serum samples were
aliquoted and stored at 80 C before use.2.2. Hemagglutination-inhibition assay (HI)
Serum samples were treated with receptor destroying enzyme
and run in the HI assay using the homologous H3N2 vaccine strain
as previously described [16]. Seroprotection was defined as an HITable 1
Study demographics.
Children <5 Children 10–1
Number 15 14
M/F (% Male) 11/4 (73%) 3/11 (21%)
Age, mean (range) 3.8 (3–5) 14.2 (10–17)
Previous influenza vaccination 4 (27%)a 7 (50%)a
a Pandemic H1N1 vaccination in 2009.
b Prior seasonal influenza vaccination and pandemic H1N1 vaccination in 2009.titerP 40. HI titers < 10 were assigned a value of 5 for calculation
purposes.
2.3. Hemagglutinin specific IgG1, IgG2, IgG3 and IgG4 ELISA
An indirect ELISA was performed in order to determine the HA-
specific IgG1, IgG2, IgG3 and IgG4 antibody concentrations in
serum samples [17,18]. Ninety-six-well plates were coated with
Influenza A/Texas/50/2012 (H3N2) -HA1 6xHis-tagged Hemagglu-
tinin (1 lg/ml) (eEnzyme) or capture IgG antibody (0.3 lg/ml).
Antibody concentrations were calculated using IgG1, IgG2, IgG3
and IgG4 standards and linear regression of the log-transformed
readings.
2.4. Hemagglutinin specific IgA1 ELISA
ELISA plates were coated as previously described for the IgG1
detection except monoclonal goat anti-human IgA (Sigma) (1 lg/
ml) and horseradish peroxidase-conjugated monoclonal mouse
anti-human IgA1 Abs (SouthernBiotech) were used as detection
antibodies.
2.5. IgG avidity ELISA
Serum samples were evaluated for avidity of HA-specific IgG
antibodies as previously described [17]. ELISA plates were coated
with Influenza A/Texas/50/2012-HA1 6xHis-tagged Hemagglutinin
(1 lg/ml) (eEnzyme). Serum samples were standardized to a dilu-
tion that gave an Optical Density of 0.7 ± 0.3 in a direct ELISA and
1.5 M Sodium thiocyanate (NaSCN) was added 1 h after the serum,
followed by 1 h of incubation. The percentage of antibodies
remaining after treatment with 1.5 M NaSCN was calculated as:
(OD450 treated serum/OD450 untreated serum)  100%.
2.6. Statistics analysis
Data analysis was performed using GraphPad Prism version 5.
Kruskal-Wallis test was used for multiple comparisons between
the four groups. Wilcoxon and Friedman tests were used to7yrs LAIV3 vaccinated adults IIV3 vaccinated adults
15 15
5/10 (33%) 2/13 (13%)
34.6 (19–59) 44.9 (26–64)
5 (33%)a 15 (100%)b
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lation between the serological assays was performed using Spear-
man rank test. A p-value <0.05 was considered statistically
significant.3. Results
3.1. LAIV3 induces age-related H3N2 HI antibody responses in children
and adults
We analyzed the seroprotective HI antibodies to H3N2 in chil-
dren vaccinated with LAIV3 and in adults vaccinated with LAIV3
or IIV3. Prior to vaccination, adults vaccinated with IIV3 had the
highest HI titers (GMT 68) with 73% having pre-existing seropro-
tective titers (HI titersP 40) compared to 40% (GMT 27.4), 43%
(GMT 21.2) and 27% (GMT 12.6) in children <5 years old, children
10–17 years old and LAIV3-vaccinated adults, respectively
(Fig. 2A). Vaccination resulted in a significant increase in HI titers
in all groups except for LAIV3-vaccinated adults (p < 0.05) (Fig. 2A
and B). High titers and seroprotection rates were observed after
vaccination in 87% (GMT 220.5), 86% (GMT 147.3) and 87% (GMT
89) of children <5 years, children 10–17 years and IIV3 vaccinated
adults, respectively. In contrast, the post-vaccination seroprotec-
tion rate in LAIV3-vaccinated adults increased slightly but was
low at 40% (GMT 20.8). The HI titers induced by LAIV3 in adults
were significantly lower than the other 3 groups (p < 0.01). Fur-Fig. 2. Hemagglutination inhibition response. (A) Geometric mean HI titers against infl
children 10–17 years old (closed circles), LAIV3 vaccinated adults (closed triangles) and II
considered protective. Each symbol represents the GMT of all the titers at each time-poi
between age and post-vaccination HI titers in LAIV3 and IIV3 vaccinated subjects. *p < 0thermore, the post-vaccination HI titers in the LAIV3-vaccinated
subjects negatively correlated with age (Spearman’s r = 0.57,
p < 0.0001) (Fig. 2C).3.2. LAIV3 after two doses in young children and IIV3 in adults induced
comparable hemagglutinin-specific IgG1 responses
Since the HI assay does not differentiate between the IgG sub-
classes, we quantified the H3N2 HA1-specific IgG1, IgG2, IgG3
and IgG4 antibodies in an ELISA assay. Pre-vaccination, HA1-
specific IgG1 levels were comparable between the children and
adults (Fig. 3A). In children <5 years old, a second vaccine dose
was required to induce a significant increase in IgG1 levels. In chil-
dren 10–17 years old one dose of LAIV3 was sufficient to induce a
significant increase in HA1-specific IgG1 concentrations. However
in adults, no change in HA1-specific IgG1 concentrations was
observed after LAIV3 vaccination. IIV3 induced a significant
increase in HA1-specific IgG1 in adults (Fig. 3A) and hence signifi-
cantly higher fold increase in IgG1 (mean 3.43 fold) than LAIV3 in
adults (mean 0.90 fold) (p = 0.008) (Fig. 3B). IIV3 induced signifi-
cantly higher IgG1 than one dose of LAIV3 in both older children
(10–17 years) and adults (p < 0.05) (Fig. 3A).
Overall, IgG3 was detected at very low concentrations in a few
subjects but was not detectable in most vaccinees (Supplementary
Fig. 1). HA1-specific IgG2 and IgG4 subclasses were absent in all
subjects tested (data not shown).uenza A H3N2/Texas virus pre- and post-vaccination in children <5 (open circles),
V3 vaccinated adults (open triangle). The dotted line indicates a titer of 40, which is
nt ± SEM (bars). (B) Pre- to post-vaccination fold change in HI titers. (C) Correlation
.05; **p < 0.01; ***p < 0.001, ****p < 0.0001.
Fig. 3. HA1-specific IgG1 response. (A) The concentration of HA1-specific IgG1 was measured in pre- and post-vaccination plasma of children <5 (open circles), children 10–
17 years old (closed circles), LAIV3 vaccinated adults (closed triangles) and IIV3 vaccinated adults (open triangle). Each symbol represents an individual. (B) Fold induction of
post-vaccination IgG1 concentrations over pre-vaccination IgG1 concentrations. ⁄ indicates statistically significant differences in responses *p < 0.05; **p < 0.01; ***p < 0.001.
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the HI assay detects HA specific antibodies, we analyzed the rela-
tionship between the HA1-specific IgG1 and HI response. We found
a significant correlation between HI titers and HA1-specific IgG1 in
LAIV3-vaccinated children and adults post-vaccination (Spear-
man’s r > 0.5, p < 0.01). However, we observed no relationship
between the HI titers and HA1-specific IgG1 response in IIV3-
vaccinated adults (Supplementary Fig. 2).
3.3. High HA-specific IgA1 responses induced by vaccination in
children but not in adults
We investigated whether LAIV3 or IIV3 induced HA1-specific
IgA1 antibodies in children and adults. Pre-vaccination, HA1-
specific IgA1 was detectable in all the groups. Significantly higher
HA1-specific IgA1 levels were found in children <5 years old com-
pared to older children aged 10–17 years (p < 0.05) (Fig. 4A). Vacci-
nation resulted in a significant increase in HA1-specific IgA1
concentrations in children but not in adults (Fig. 4A). Young chil-
dren who received two vaccine doses had significantly higherFig. 4. HA1-specific IgA1 response. (A) IgA1 antibodies specific to HA1 in children <5 (op
triangles) and IIV3 vaccinated adults (open triangle) pre- and post-vaccination. (B) Pre-HA1-specific IgA1 after the second dose than older children and
adults who all received one vaccine dose (p < 0.05). Although LAIV3
or IIV3 did not result in a significant increase in IgA1 levels in
adults, the IgA1 concentrations and fold changes were maintained
at similar levels to those in older children (10–17 years) who also
received one vaccine dose (Fig. 4B).
3.4. Vaccination induced high avidity antibodies in children and adults
To assess the difference in quality of the IgG antibodies induced
by LAIV3 and IIV3, the avidity of HA1-specific IgG antibodies was
measured. The percentage of bound IgG antibodies remaining after
treatment with 1.5 M NaSCN was calculated. The avidity of HA1-
specific IgG antibodies was comparable between young and older
children, as well as between the two adult groups, pre-
vaccination (Fig. 5A). However, the avidity of HA1-specific IgG
antibodies in older children (10–17 years) was significantly lower
than that of the two adult groups (p < 0.05). Vaccination resulted
in a significant increase in antibody avidity in children <5 years
old, children 10–17 years old and IIV3-vaccinated adults but noten circles), children 10–17 years old (closed circles), LAIV3 vaccinated adults (closed
to post-vaccination fold change in HA1 specific IgA1. *p < 0.05; **p < 0.01.
Fig. 5. Hemagglutinin specific IgG antibody avidity. (A) The avidity of HA1 specific total IgG antibodies was measured in an avidity ELISA assay for children <5 (open circles),
children 10–17 years old (closed circles), LAIV3 vaccinated adults (closed triangles) and IIV3 vaccinated adults (open triangle) pre- and post-vaccination. Standardized sera
were treated with 1.5 M NaSCN and the percentage of HA1-specific IgG antibodies remaining bound after 1.5 M NaSCN treatment was measured as (absorbance of treated
samples  absorbance of untreated samples)  100%. The line represents the mean avidity index at each time-point ± SEM. The stacked column graphs represent the
percentage of (B) children and (C) adults with high avidity antibodies (avidity indexP 20%). The percentage of subjects with antibodies with <20% avidity are shown in white
while those with avidity indexP 20% are shown in black. *p < 0.05; **p < 0.01.
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37.5% and 44.4%, respectively (Fig. 5A). Even though the avidity
of IgG antibodies in LAIV3-vaccinated adults did not increase, anti-
bodies post-vaccination were characterized by high avidity, com-
parable to the other three groups.
We used a cut-off avidity index of 20% to determine which sub-
jects had high avidity antibodies. Pre-vaccination, a higher number
of adults compared to children showed high avidity (>20% avidity
index) antibodies. The frequency of children <5 years old, children
10–17 years old, LAIV3-vaccinated adults and IIV3-vaccinated
adults with pre-existing high avidity antibodies were 46%, 25%,
75% and 80%, respectively (Fig. 5B and C). Post-vaccination, the
proportion of children with high avidity IgG increased from 46%
to 69% and from 25% to 75% in <5 year olds and 10–17 year olds,
respectively. Both LAIV3-vaccinated and IIV3-vaccinated adults
maintained elevated antibody avidity with 83% and 100% having
high avidity antibodies, respectively (Fig. 5C).
Interestingly, we found a positive correlation between the avid-
ity of pre-existing HA-specific IgG and post vaccination HA1-
specific IgG1 response in children <5 (spearman’s r = 0.71,
p = 0.0068) and children 10–17 years old (spearman’s r = 0.72,p = 0.01) (Supplementary Fig. 3). However, this correlation was
not observed in either LAIV3 or IIV3 vaccinated adults.
4. Discussion
Annual influenza vaccination is the most effective method to pre-
vent infection especially in subjects prone to develop secondary
complications, such as young children, pregnant women, people
with chronic medical conditions and the elderly [18]. Both mucosal
and systemic antibodies have been previously shown to be involved
in the protection against influenza infection [11,19,20]. Antibodies
specific to the HA1 domain of HA, which contains the receptor-
binding site, are important for viral neutralization [21,22]. However,
the immune response after vaccination may be influenced by several
factors, including vaccine type and age of recipients [5,23,24]. Here,
we evaluated the quantity as well as the quality of the antibodies
specific to H3N2 HA induced by LAIV3 and IIV3 in 4 different partic-
ipant groups, varying by age and vaccine type.
LAIV vaccines contain live, cold-adapted influenza viruses that
only replicate in the mucosal membranes of the upper respiratory
tract (<33 C), causing only mild subclinical infection in humans
196 A. Manenti et al. / Vaccine 35 (2017) 191–198[26,27]. LAIV promotes a robust antibody response in young chil-
dren, especially in individuals that are seronegative pre-
vaccination [28–30]. Previous studies demonstrated that LAIV3
was more effective than IIV3 in children aged from 6 months to
17 years old [25,26]. A study comparing the efficacy and safety of
LAIV3 versus IIV3 in children with recurrent respiratory tract infec-
tions showed that LAIV3 resulted in a 53% reduction in influenza
cases by antigenically matched vaccine strains compared to IIV3
[25]. Another study by Fleming et al. reported 35% fewer influenza
cases in LAIV3 recipients compared to IIV3 recipients [26].
Although at present no immunological correlates of protection
are available for LAIV, our HI assay results confirm that LAIV3
induces a significant antibody response in children of all ages.
A study by Treanor et al. showed that IIV3 induced higher HI
titers than LAIV3 in adults, with titers induced by LAIV3 being
comparable to placebo. However, after challenge with wild type
virus of vaccinated adults with HI titers6 8, laboratory confirmed
illness occurred in 13%, 7% and 45% of IIV3, LAIV3 and placebo vac-
cinated adults, respectively [27]. They demonstrated that despite
low HI titers, LAIV3 had comparable efficacy to IIV3 in adults. We
showed that IIV3 induces significantly higher HI titers than LAIV3
in adults, with LAIV3 resulting in no increase in titers. Despite no
increase in HI titers after LAIV3 vaccination in adults, they could still
be protected by other immune mechanisms [28–30].
In Norway, seasonal influenza vaccination is only recommended
for children with high-risk conditions and the children in our study
were healthy and therefore not previously vaccinated. Only 27% of
children <5 years old and 50% of children 10–17 years old had
received pandemic H1N1 influenza vaccination in 2009. However,
six children <5 years had high HI titers (>160) and IgG1 levels
against H3N2 virus. Also five children, 10–17 years old had HI
titers > 40. These children are likely to have been previously exposed
to H3N2 through natural infection explaining the high HI titers.
In this study, we investigated the IgG subclass response to
H3N2 HA, since it is the most dominant serum immunoglobulin
class induced after vaccination [25]. IgG1, along with IgG3, are
involved in critical immunologic functions such as complement
fixation, opsonization, antibody-dependent cellular cytotoxicity
and virus neutralization [34]. In general, we detected elevated
IgG1 levels in our subjects, whereas IgG3 levels were low post-
vaccination. Both unvaccinated and previously vaccinated children
and adults had pre-existing HA1-specific IgG1 reflecting previous
exposure to antigenically similar influenza viruses [31,32]. Based
on the significant increase in IgG1 antibodies in children, LAIV3
appears to be efficient in both priming the H3N2 response in the
children with no pre-existing titers and boosting this response in
children with pre-existing titers.
IIV3 vaccine elicits a more robust increase in serum IgG anti-
bodies, with only a minor induction of local IgA response [33,34].
Conversely, LAIV induces higher local IgA response at the nasal
epithelium and lower systemic antibody responses [38]. Since
the LAIV mimics a natural infection, which stimulates a local IgA
response providing protection at the local mucosa where the influ-
enza virus starts its infection cycle. Children who had high HI titers
also had high IgA1 levels and the higher pre-vaccination IgA1
observed in children <5 compared to older children could be due
to the difference in numbers of children who had previous infec-
tion with H3N2 (supplementary Fig. 4). Our study of systemic
IgA1 response revealed that whereas no change was observed after
LAIV3 or IIV3 vaccination in adults, a significant increase was
found in serum IgA1 in children after LAIV3. Particularly, younger
children receiving two vaccine doses of LAIV3 showed significantly
higher IgA levels compared to older children (10–17 years) who
received a single dose of vaccine. The IgA1 response detected in
our study could also be due to spill over of IgA from the site of vac-
cination at the local mucosa. However, we did not measure thenasal antibody response. A study by Boyce et al. demonstrated a
positive correlation between nasal and serum IgG and IgA
responses in adults intranasally vaccinated with inactivated vac-
cine [35]. Another study demonstrated elevated serum antibody
titers positively correlated with nasal antibody levels. In addition,
LAIV increased mucosal IgA but not systemic IgG in adults [36].
Our results are in agreement with these observations, as LAIV3
did not induce a significant increase in systemic IgG1 or IgA1 in
adults. An earlier investigation showed that pre-existing nasal
IgA, detected almost exclusively in subjects naturally infected or
vaccinated with LAIV, was associated with protection [37]. Adults
would have had a number of exposures to influenza in their life-
time either through vaccination or infection. It is plausible that
pre-existing antibodies were present in the nasopharyngeal
mucosa of the adults before vaccination, which may limit both
intranasal infection and replication of LAIV, resulting in a lower
antibody response as observed in our LAIV3-vaccinated adults [38].
The pre-existing HA1-specific IgG antibodies in children 10–
17 years old had low avidity compared to adults. The high antibody
avidity observed pre-vaccination in a few children and most adults
may be due to pre-existing memory generated by previous infec-
tion. Avidity could indicate the priming of immunological memory
as vaccination results in antibody maturation and hence genera-
tion of antibodies with increased avidity as we detected in the pre-
sent study [37,39]. Priming and subsequent boosting of the
antibody response results in a gradual increase in high affinity
antibodies. Of note is that adults who received the IIV3 were
healthcare workers who are offered yearly influenza vaccination
and are also likely to come in contact with infected patients. We
have previously reported that repeated annual vaccination in
healthcare workers persistently boosted the avidity of influenza-
specific IgG antibodies [40]. The high avidity antibodies were
maintained in LAIV3-vaccinated adults, although they did not
increase in quantity or quality post-vaccination. Interestingly, the
avidity of pre-existing antibodies predicted the IgG1 response in
children. This suggests that vaccination and infection outcome in
children likely correlates with the quality of the antibodies and
their ability to restrict virus replication to the upper respiratory
tract. In adults, the elevated pre-existing IgG avidity was not asso-
ciated with a higher IgG1 concentration after vaccination, suggest-
ing that a low number of high avidity memory B cells could be
sufficient for the maintenance of protection in previously vacci-
nated or exposed individuals.
This study was limited by several factors. First, small number of
subjects was included per group, thus limiting the statistical com-
parisons that could be made. Another limitation is that we did not
measure mucosal IgA; which is particularly important after LAIV
however, our study objective was to measure both serum IgG
and IgA antibody responses.
In conclusion, our findings confirm that LAIV3 promotes a
stronger systemic antibody response in children than in adults.
In adults, IIV3 induces better antibody responses compared to
LAIV3, but comparable antibody response to that induced in
LAIV3-vaccinated children. The different mechanisms of action of
LAIV3 versus IIV3, may explain the relative efficacy between the
two vaccines in children and adults. In children, the avidity of
pre-existing serum antibodies likely plays a role in determining
the antibody response to infection. Our results suggest that expo-
sure history and the type of vaccine play a significant role in deter-
mining the antibody response.
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